Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Nephrotic Syndrome 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Kidney Diseases 1Immunoglobulin Light-chain Amyloidosis 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Arthritis, Rheumatoid 1Amyloidosis 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Sorafenib 2Oxaliplatin 2Leucovorin 2Interleukin-2 2Fluorouracil 2Denosumab 2Bortezomib 2Bevacizumab 2venetoclax 1vactosertib 1trametinib 1temsirolimus 1sargramostim 1ruxolitinib 1repotrectinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Pharmaceutical Preparations × Plasma cell × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡